Suven Pharmaceuticals Limited
SUVENPHAR.NS
National Stock Exchange of India1,078.00
INR
-1.20
- -
Suven Pharmaceuticals Limited
SUVENPHAR.NS
(National Stock Exchange of India)
Recent
price
1,078.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Suven Pharmaceuticals Limited is an Indian biopharmaceutical company specializing in contract research and manufacturing services (CRAMS), contract development and manufacturing organization (CDMO) services, and active pharmaceutical ingredient (API) manufacturing. The company focuses primarily on novel drug discovery and development in the central nervous system (CNS) therapeutic segment, including treatments for anxiety, depression, and neurodegenerative diseases. Its product offerings include new chemical entities (NCEs), generic pharmaceuticals, specialty chemicals, and nutraceutical products, supported by comprehensive services such as product development, clinical supplies manufacturing, analytical services, and regulatory management. Suven operates multiple manufacturing facilities in India, serving global pharmaceutical and agrochemical companies, and maintains GMP-compliant production capabilities. Founded in 1989 and headquartered in Telangana, India, Suven has built a significant presence in both domestic and international pharmaceutical markets. In recent developments, Suven Pharmaceuticals completed a major strategic merger with Cohance Lifesciences Limited effective May 1, 2025, creating a combined entity named Cohance Lifesciences Limited. This merger expanded Suven’s capabilities in advanced modalities such as antibody-drug conjugates (ADC), oligonucleotides, and complex chemistry platforms, significantly broadening its CDMO and API service offerings. The combined entity aims to enhance its global footprint and accelerate innovation and execution across the pharmaceutical value chain. Additionally, Suven acquired a majority stake in Sapala Organics, strengthening its CDMO presence and diversifying into specialty chemicals. Suven also announced an agreement to acquire a controlling stake in NJ Bio, Inc., a biotechnology company, further expanding its research and manufacturing capabilities. These initiatives are part of a broader strategy supported by Advent International, a private equity investor that completed a majority acquisition of Suven in 2023 and is exploring a buy-and-build approach to enhance Suven’s market position and revenue growth. Suven Pharmaceuticals is committed to innovation with substantial investment in research and development, focusing on neuropharmacology and chronic disease therapies. The company has launched over 20 new formulations aimed at improving patient outcomes and reducing healthcare costs, particularly in the CNS segment. It upholds stringent quality standards, holding WHO-GMP and ISO certifications, and emphasizes operational excellence through continuous process improvements. Suven’s revenue has shown strong growth driven by its flagship products and expanding contract services, with a strategic emphasis on integrating complementary technologies and customer networks following recent mergers and acquisitions. The company operates across India with global outreach, targeting multinational pharmaceutical companies and biotech firms as its primary customer segments. Suven Pharmaceuticals Limited, through its subsidiaries and merged entities, is poised for significant growth as it leverages its expanded portfolio and integrated capabilities in drug discovery, development, and manufacturing services to strengthen its competitive edge in the global pharmaceutical industry.